Monoclonal selection based on antibody-peptide affinity, full characterization of antibody-antigen kinetics using Surface Plasmon Resonance, internalization dynamics, in vitro toxicity in cancer cell lines and in vivo bio-distribution and toxicology identified antibodies targeting the V-region of RAGE as suitable candidates for pre-clinical development. This evidence concerns the gene AGER and cancer.